Analysts have been eager to weigh in on the Healthcare sector with new ratings on PTC Therapeutics (PTCT) and Audentes Therapeutics (BOLD).
PTC Therapeutics (PTCT)
In a report released yesterday, Joseph Thome from Cowen & Co. maintained a Hold rating on PTC Therapeutics. The company’s shares closed yesterday at $44.75.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for PTC Therapeutics with a $55 average price target.
See today’s analyst top recommended stocks >>
Audentes Therapeutics (BOLD)
In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Audentes Therapeutics. The company’s shares closed yesterday at $37.03.
According to TipRanks.com, Baral is a 5-star analyst with an average return of 21.7% and a 46.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Audentes Therapeutics with a $46.50 average price target, implying a 25.6% upside from current levels. In a report issued on July 29, Raymond James also resumed coverage with a Buy rating on the stock with a $46 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
